Brightworks helps NeoGenomics support cancer patients during COVID

Seeing the barriers limiting patient access to crucial oncology diagnostic testing services,  NeoGenomics launched a new Mobile Phlebotomy Testing Service in November 2020 to help ensure no patient experiences delays in their care – and they did it in a way that was free to the patient. NeoGenomics tasked Brightworks to create a launch campaign that would announce this new offering to the US market. 

With a restricted budget and timeline, this encompassed: 

• • 1-Page Sales Sheet
• • CEO Announcement Video
• • Animated Informational Video
• • Social post content support (in collaboration with the client’s internal creative team)
• • Leverage this short list of assets to:
• • Communicate that NeoGenomics cares – they will come to patients to support them during the challenging times created by COVID-19
• • Showcase NeoGenomics’ leadership within oncology diagnostics and their commitment to improving oncology patient care through evolving their oncology diagnostics offering 

• • Despite timeline challenges, all assets were launch day ready – so important in a therapeutic space where even a 1-day delay can impact a patient’s well-being.
• • Successfully balanced the need to communicate to numerous audiences with limited assets: from pathologists and oncologists, to patients, pharma partners and business analysts.
• • Supported the client in smoothly rolling out this new program to their target HCPs, effectively helping physicians to better support their patients and gain access to important diagnostic information in the timeliest fashion possible, while taking COVID-19 limitations into consideration.